Supernus Pharma (SUPN) Misses Q3 EPS by 32c

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.03, $0.32 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $177.35 million versus the consensus estimate of $172.94 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
• Barclays says AI trade is maturing, favors greater diversification